Rush University Medical Center Hematology and Medical Oncology

Topics

• Acute Myeloid Leukemia Research 106
• Hematopoietic Stem Cell Transplantation 55
• Lymphoma Diagnosis and Treatment 44
• HER2/EGFR in Cancer Research 34
• Mast cells and histamine 33
• Chronic Lymphocytic Leukemia Research 28
• Lung Cancer Treatments and Mutations 27
• Breast Cancer Treatment Studies 25
• Head and Neck Cancer Studies 24
• Cancer Immunotherapy and Biomarkers 21
• Lung Cancer Diagnosis and Treatment 21
• Hemoglobinopathies and Related Disorders 17

Most cited

1. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 202 citations · Celalettin Ustun

2. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.

   HemaSphere · 2021 · 257 citations · Celalettin Ustun

3. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.

   Blood · 2025 · 52 citations · Celalettin Ustun

4. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 57 citations · Mary Fidler

5. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.

   Blood · 2021 · 170 citations · Sunita Nathan

6. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC).

   NPJ breast cancer · 2025 · 49 citations ·